Timing of donor lymphocyte infusion after relapse following allogeneic hematopoietic cell transplantation: a retrospective single-center analysis
Annals of Hematology · 30.05.2026 · 105 (6)
DOI: 10.1007/s00277-026-07090-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 30.05.2026. Verfasst von Alexander C Angleitner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University Medical Hospital Goettingen, Robert Koch-Straße 40, +49 551 -3962051, 37075, Goettingen, Germany. a…. Hauptthemen laut MEDLINE: Lymphocyte Transfusion, Hematopoietic Stem Cell Transplantation, Transplantation, Heterologous. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Herzzentrum Göttingen.
Abstract (Originalsprache)
Donor lymphocyte infusions (DLI) are an important strategy for managing relapse after allogeneic hematopoietic stem cell transplantation (allo-HCT), yet data on the impact of surveillance frequency and DLI timing remain limited. We retrospectively analyzed 83 adults with acute leukemia or MDS who received DLI after relapse between 2010 and 2022. Monthly molecular monitoring with donor chimerism and genetic markers enabled classification of preemptive DLI at molecular relapse and therapeutic DLI at overt hematologic relapse. Overall survival (OS) was assessed using Kaplan–Meier estimates and Cox regression. Therapeutic DLI was associated with inferior OS compared with preemptive DLI (HR = 0.15 in multivariable analysis, p < 0.001); median OS was 0.47 years in the therapeutic group, while it was not reached after preemptive DLI. GvHD after DLI was associated with better OS (HR = 0.28), consistent with graft-versus-leukemia effects. A longer interval between allo-HCT and relapse also predicted improved survival (HR = 0.78). Delivering DLI at molecular rather than hematologic relapse improved survival, suggesting that close MRD-based surveillance enables earlier detection, timely immunologic intervention, and may improve post-relapse outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, University Medical Hospital Goettingen, Robert Koch-Straße 40, +49 551 -3962051, 37075, Goettingen, Germany. alexander.angleitner@med.uni-goettingen.de.
- Department of Hematology and Oncology, University Medical Hospital Goettingen, Robert Koch-Straße 40, +49 551 -3962051, 37075, Goettingen, Germany.
Förderung
- Herzzentrum Göttingen
Zitieren
APA
Angleitner, A. C., Maulhardt, M., Treiber, H., Hasenkamp, J., Büntzel, J., & Wulf, G. G. (2026). Timing of donor lymphocyte infusion after relapse following allogeneic hematopoietic cell transplantation: a retrospective single-center analysis. Annals of Hematology, 105(6). https://doi.org/10.1007/s00277-026-07090-1
Vancouver
Angleitner AC, Maulhardt M, Treiber H, Hasenkamp J, Büntzel J, Wulf GG. Timing of donor lymphocyte infusion after relapse following allogeneic hematopoietic cell transplantation: a retrospective single-center analysis. Annals of Hematology. 2026;105(6). doi:10.1007/s00277-026-07090-1
BibTeX
@article{Angleitner2026,
author = {Angleitner, Alexander C and Maulhardt, Markus and Treiber, Hannes and Hasenkamp, Justin and Büntzel, Judith and Wulf, Gerald G},
title = {Timing of donor lymphocyte infusion after relapse following allogeneic hematopoietic cell transplantation: a retrospective single-center analysis},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {6},
doi = {10.1007/s00277-026-07090-1}
}
EUVIMED